glp-1 receptor agonist news Agonists: The New Wave in Diabetes Management Study finds GLP-1 receptor agonists

Horowitz, H

is an advisor to the US FDA, EMA, MHRA, the US Senate, and the White House, and is a developer of novel biological drugs

Once an effective dose is reached and HbA1c targets are met, the focus shifts to maintenance

Additionally, biotechnology and pharmaceutical companies are examining how to repurpose molecules implicated in skeletal muscle pathways (such as myostatin/activin, apelin, and mTOR), and developing new molecules and medications to maintain SMM while benefiting from GLP-1 medications' positive health effects

Table 4 lists the agents currently available in the USA and their dosing strategies [19, 38, 55,56,57,58]

But given just how miraculous semaglutide is for obesity, and given the miraculous anecdotes , I dont see how to spin this paper as anything but a letdown